Table 2 SVR rate by regimen, cirrhosis status and prior treatment history
From: A new paradigm evaluating cost per cure of HCV infection in the UK
Total (n = 145a) | Treatment-naïve patients (n = 74) | Prior relapsers (n = 35) | Prior non-responders (n = 36) |
|---|---|---|---|
SVR rate | 68.9 % [57.1;79.2] | 82.9 % [66.4;93.4] | 33.3 % [18.6;51.0] |
By regimen | |||
BOC triple therapy (n = 48) | 66.7 % [47.2;82.7] (n = 30) | 75.0 % [34.9;96.8] (n = 8) | 30.0 % [6.7;65.2] (n = 10) |
TVR triple therapy (n = 97) | 70.4 % [54.8;83.2] (n = 44) | 85.2 % [66.3;95.8] (n = 27) | 34.6 % [17.2;55.7] (n = 26) |
By liver disease stage | |||
No-cirrhosis (n = 114) | 73.8 % [61.5;84.0] (n = 65) | 86.2 % [68.3;96.1] (n = 29) | 40.0 % [19.1;64.0] (n = 20) |
Cirrhosis or HCC (n = 31) | 33.3 % [7.5;70.1] (n = 9) | 66.7 % [22.3;95.7] (n = 6) | 25.0 % [7.3;52.4] (n = 16) |